{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T23:23:23Z","timestamp":1793748203118,"version":"4.6.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:00:00Z","timestamp":1771027200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000057","name":"U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["R35GM145351"],"award-info":[{"award-number":["R35GM145351"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000070","name":"U.S. Department of Health & Human Services | NIH | National Institute of Biomedical Imaging and Bioengineering","doi-asserted-by":"publisher","award":["R21EB032983"],"award-info":[{"award-number":["R21EB032983"]}],"id":[{"id":"10.13039\/100000070","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R21AI164088"],"award-info":[{"award-number":["R21AI164088"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Anecdotal reports about smoking that might prevent SARS-CoV-2 infection inspire the search for nicotine and its pyrolysis products as inhibitors of the SARS-CoV-2 main protease (M\n                    <jats:sup>Pro<\/jats:sup>\n                    ). This effort leads to the discovery of 3-vinylpyridine as an M\n                    <jats:sup>Pro<\/jats:sup>\n                    inhibitor. 3-Vinylpyridine resembles part of nirmatrelvir in binding to M\n                    <jats:sup>Pro<\/jats:sup>\n                    but does not involve a critical interaction with residue E166, whose mutation has led to resistance to nirmatrelvir. Integration of the two molecules, followed by a medicinal chemistry campaign, produces several molecules with better in vitro potency than nirmatrelvir. Two lead molecules, YR-C-136 and SR-B-103, display better pharmacokinetic characteristics than nirmatrelvir in virus-challenged male mice and much better antiviral efficacy in virus-challenged female mice. Both molecules maintain high potency in inhibiting the nirmatrelvir-resistant M\n                    <jats:sup>Pro<\/jats:sup>\n                    (E166V\/L50F) variant. They also exhibit a broad and highly potent antiviral spectrum against most pathogenic coronaviruses. With high in vivo potency, both molecules are potentially standalone pan-antivirals for coronaviruses and may serve as countermeasures for future coronavirus outbreaks.\n                  <\/jats:p>","DOI":"10.1038\/s41467-026-69527-5","type":"journal-article","created":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T14:35:51Z","timestamp":1771079751000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["From nicotine to SARS-CoV-2 antivirals with potent in vivo efficacy and a broad anti-coronavirus spectrum"],"prefix":"10.1038","volume":"17","author":[{"given":"Kaustav","family":"Khatua","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Atla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Demonta","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren R.","family":"Blankenship","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yugendar R.","family":"Alugubelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6224-5674","authenticated-orcid":false,"given":"Veerabhadra","family":"Vulupala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejiao Shirley","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2520-7038","authenticated-orcid":false,"given":"Hongjie","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birte K.","family":"Kalveram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1025-5878","authenticated-orcid":false,"given":"Brett L.","family":"Hurst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sathish","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Chuan D.","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7262-6805","authenticated-orcid":false,"given":"Shivangi","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorsa","family":"Rabie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satyanarayana","family":"Nyalata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1240-8954","authenticated-orcid":false,"given":"Benjamin W.","family":"Neuman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0918-016X","authenticated-orcid":false,"given":"Xuping","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6260-9290","authenticated-orcid":false,"given":"Shiqing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7078-6534","authenticated-orcid":false,"given":"Wenshe Ray","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,14]]},"reference":[{"key":"69527_CR1","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","volume":"579","author":"P Zhou","year":"2020","unstructured":"Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270\u2013273 (2020).","journal-title":"Nature"},{"key":"69527_CR2","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1126\/science.abc8169","volume":"370","author":"M Worobey","year":"2020","unstructured":"Worobey, M. et al. The emergence of SARS-CoV-2 in Europe and North America. Science 370, 564\u2013570 (2020).","journal-title":"Science"},{"key":"69527_CR3","doi-asserted-by":"publisher","first-page":"abm0829","DOI":"10.1126\/science.abm0829","volume":"374","author":"RR Goel","year":"2021","unstructured":"Goel, R. R. et al. mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. Science 374, abm0829 (2021).","journal-title":"Science"},{"key":"69527_CR4","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/s41586-020-2622-0","volume":"586","author":"KS Corbett","year":"2020","unstructured":"Corbett, K. S. et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature 586, 567\u2013571 (2020).","journal-title":"Nature"},{"key":"69527_CR5","unstructured":"World Health Organization, COVID-19 Epidemiological Update - 12 March Edition 177, 1\u201331 (2025)."},{"key":"69527_CR6","unstructured":"Mathieu, E. et al. Coronavirus Pandemic (COVID-19). Our World in Data, (2020\u20132024)."},{"key":"69527_CR7","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41579-020-00468-6","volume":"19","author":"P V\u2019Kovski","year":"2021","unstructured":"V\u2019Kovski, P., Kratzel, A., Steiner, S., Stalder, H. & Thiel, V. Coronavirus biology and replication: implications for SARS-CoV-2. Nat. Rev. Microbiol. 19, 155\u2013170 (2021).","journal-title":"Nat. Rev. Microbiol."},{"key":"69527_CR8","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.cell.2020.04.011","volume":"181","author":"D Kim","year":"2020","unstructured":"Kim, D. et al. The Architecture of SARS-CoV-2 Transcriptome. Cell 181, 914\u2013921 e910 (2020).","journal-title":"Cell"},{"key":"69527_CR9","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1002\/cbic.202000047","volume":"21","author":"JS Morse","year":"2020","unstructured":"Morse, J. S., Lalonde, T., Xu, S. & Liu, W. R. Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV. Chembiochem 21, 730\u2013738 (2020).","journal-title":"Chembiochem"},{"key":"69527_CR10","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1126\/science.abb4489","volume":"368","author":"W Dai","year":"2020","unstructured":"Dai, W. et al. Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. Science 368, 1331\u20131335 (2020).","journal-title":"Science"},{"key":"69527_CR11","unstructured":"Boby, M. et al. Open science discovery of potent noncovalent SARS-CoV-2 main protease inhibitors. Science 382, eabo7201 (2023)."},{"key":"69527_CR12","doi-asserted-by":"crossref","unstructured":"Focosi, D., Sullivan, D. J. & Franchini, M. Development of antiviral drugs for COVID-19 in 2025: unmet needs and future challenges. Expert Rev. Anti-Infect. 23, 1\u20138 (2025).","DOI":"10.1080\/14787210.2025.2473044"},{"key":"69527_CR13","doi-asserted-by":"publisher","first-page":"8686","DOI":"10.1021\/acs.jmedchem.2c00404","volume":"65","author":"KS Yang","year":"2022","unstructured":"Yang, K. S., Leeuwon, S. Z., Xu, S. & Liu, W. R. Evolutionary and structural insights about potential SARS-CoV-2 Evasion of Nirmatrelvir. J. Med Chem. 65, 8686\u20138698 (2022).","journal-title":"J. Med Chem."},{"key":"69527_CR14","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1126\/science.abl4784","volume":"374","author":"DR Owen","year":"2021","unstructured":"Owen, D. R. et al. An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19. Science 374, 1586\u20131593 (2021).","journal-title":"Science"},{"key":"69527_CR15","doi-asserted-by":"publisher","first-page":"6499","DOI":"10.1021\/acs.jmedchem.2c00117","volume":"65","author":"Y Unoh","year":"2022","unstructured":"Unoh, Y. et al. Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19. J. Med. Chem. 65, 6499\u20136512 (2022).","journal-title":"J. Med. Chem."},{"key":"69527_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42102-y","volume":"14","author":"X Jiang","year":"2023","unstructured":"Jiang, X. et al. Structure-based development and preclinical evaluation of the SARS-CoV-2 3C-like protease inhibitor simnotrelvir. Nat. Commun. 14, 6463 (2023).","journal-title":"Nat. Commun."},{"key":"69527_CR17","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00539-24","volume":"68","author":"J Zhou","year":"2024","unstructured":"Zhou, J. et al. Pharmacokinetics and safety of GST-HG171, a novel 3CL protease inhibitor, in Chinese subjects with impaired and normal liver function. Antimicrob. Agents Ch 68, e0053924 (2024).","journal-title":"Antimicrob. Agents Ch"},{"key":"69527_CR18","doi-asserted-by":"publisher","first-page":"102359","DOI":"10.1016\/j.eclinm.2023.102359","volume":"67","author":"Y Zhan","year":"2024","unstructured":"Zhan, Y. et al. Leritrelvir for the treatment of mild or moderate COVID-19 without co-administered ritonavir: a multicentre randomised, double-blind, placebo-controlled phase 3 trial. Eclinicalmedicine 67, 102359 (2024).","journal-title":"Eclinicalmedicine"},{"key":"69527_CR19","doi-asserted-by":"crossref","unstructured":"Amani, B. & Amani, B. Efficacy and safety of nirmatrelvir\/ritonavir (Paxlovid) for COVID-19: A rapid review and meta-analysis. J. Med. Virol. 95, 1\u20139 (2023).","DOI":"10.1002\/jmv.28441"},{"key":"69527_CR20","doi-asserted-by":"crossref","unstructured":"Luetkemeyer A. F. et al. Ensitrelvir for the treatment of nonhospitalized adults with COVID-19: Results from the SCORPIO-HR, Phase 3, Randomized, double-blind, placebo-controlled trial. Clin. Infect. Dis. 80, 1235\u20131244 (2025).","DOI":"10.1093\/cid\/ciaf029"},{"key":"69527_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/iid3.70174","volume":"13","author":"X Chen","year":"2025","unstructured":"Chen, X. et al. Effectiveness and Safety of Simnotrelvir\/Ritonavir and Nirmatrelvir\/Ritonavir in the Treatment of Moderate to Severe COVID-19. Immun. Inflamm. Dis. 13, e70174 (2025).","journal-title":"Immun. Inflamm. Dis."},{"key":"69527_CR22","doi-asserted-by":"publisher","first-page":"102582","DOI":"10.1016\/j.eclinm.2024.102582","volume":"71","author":"H Lu","year":"2024","unstructured":"Lu, H. et al. Efficacy and safety of GST-HG171 in adult patients with mild to moderate COVID-19: a randomised, double-blind, placebo-controlled phase 2\/3 trial. Eclinicalmedicine 71, 102582 (2024).","journal-title":"Eclinicalmedicine"},{"key":"69527_CR23","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.add7197","volume":"8","author":"Y Zhou","year":"2022","unstructured":"Zhou, Y. et al. Nirmatrelvir-resistant SARS-CoV-2 variants with high fitness in an infectious cell culture system. Sci. Adv. 8, eadd7197 (2022).","journal-title":"Sci. Adv."},{"key":"69527_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-51924-3","volume":"15","author":"M Nooruzzaman","year":"2024","unstructured":"Nooruzzaman, M. et al. Emergence of transmissible SARS-CoV-2 variants with decreased sensitivity to antivirals in immunocompromised patients with persistent infections. Nat. Commun. 15, 7999 (2024).","journal-title":"Nat. Commun."},{"key":"69527_CR25","doi-asserted-by":"crossref","unstructured":"Miyara, M. et al. Low rate of daily active tobacco smoking in patients with symptomatic COVID-19. Qeios 8, 668995 (2020).","DOI":"10.32388\/WPP19W"},{"key":"69527_CR26","doi-asserted-by":"crossref","unstructured":"Patanavanich, R. & Glantz, S. A. Smoking is Associated with COVID-19 Progression: A Meta-Analysis. Nicotine & Tob. Res., 22, 1653\u20131656 (2020).","DOI":"10.1093\/ntr\/ntaa082"},{"key":"69527_CR27","doi-asserted-by":"crossref","unstructured":"Israel, A., Feldhamer, E., Lahad, A., Levin-Zamir, D. & Lavie, G. Smoking and the risk of COVID-19 in a large observational population study. medRxiv, 2020.06.01.20118877 (2020).","DOI":"10.1101\/2020.06.01.20118877"},{"key":"69527_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e17783","volume":"9","author":"S Chattopadhyay","year":"2023","unstructured":"Chattopadhyay, S., Malayil, L., Kaukab, S., Merenstein, Z. & Sapkota, A. R. The predisposition of smokers to COVID-19 infection: A mini-review of global perspectives. Heliyon 9, e17783 (2023).","journal-title":"Heliyon"},{"key":"69527_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-20657-y","volume":"12","author":"M Rahman","year":"2022","unstructured":"Rahman, M. et al. Insight into the pulmonary molecular toxicity of heated tobacco products using human bronchial and alveolar mucosa models at air-liquid interface. Sci. Rep. -Uk 12, 16396 (2022).","journal-title":"Sci. Rep. -Uk"},{"key":"69527_CR30","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1002\/cmdc.202000924","volume":"16","author":"KS Yang","year":"2021","unstructured":"Yang, K. S. et al. A quick route to multiple highly potent SARS-CoV-2 main protease inhibitors. ChemMedChem 16, 942\u2013948 (2021).","journal-title":"ChemMedChem"},{"key":"69527_CR31","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1021\/ac9900533","volume":"71","author":"NA Stevens","year":"1999","unstructured":"Stevens, N. A. & Borgerding, M. F. GC-AED studies of nicotine fate in a burning cigarette. Anal. Chem. 71, 2179\u20132185 (1999).","journal-title":"Anal. Chem."},{"key":"69527_CR32","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.bbrc.2012.08.015","volume":"425","author":"I Schechter","year":"2012","unstructured":"Schechter, I. & Berger, A. On the size of the active site in proteases. I. Papain. Biochem. Biophys. Res Co. 425, 497\u2013502 (2012).","journal-title":"Biochem. Biophys. Res Co."},{"key":"69527_CR33","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","volume":"582","author":"Z Jin","year":"2020","unstructured":"Jin, Z. et al. Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors. Nature 582, 289\u2013293 (2020).","journal-title":"Nature"},{"key":"69527_CR34","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.abb3405","volume":"368","author":"L Zhang","year":"2020","unstructured":"Zhang, L. et al. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved alpha-ketoamide inhibitors. Science 368, 409\u2013412 (2020).","journal-title":"Science"},{"key":"69527_CR35","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2012201118","volume":"118","author":"EC Vatansever","year":"2021","unstructured":"Vatansever, E. C. et al. Bepridil is potent against SARS-CoV-2 in vitro. Proc. Natl. Acad. Sci. USA 118, e2012201118 (2021).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"69527_CR36","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1038\/s41564-024-01618-9","volume":"9","author":"X Chen","year":"2024","unstructured":"Chen, X. et al. Preclinical evaluation of the SARS-CoV-2 M(pro) inhibitor RAY1216 shows improved pharmacokinetics compared with nirmatrelvir. Nat. Microbiol. 9, 1075\u20131088 (2024).","journal-title":"Nat. Microbiol."},{"key":"69527_CR37","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/j.str.2023.06.010","volume":"31","author":"C Lin","year":"2023","unstructured":"Lin, C. et al. Structural basis for the inhibition of coronaviral main proteases by ensitrelvir. Structure 31, 1016\u20131024 e1013 (2023).","journal-title":"Structure"},{"key":"69527_CR38","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1093\/cid\/ciad494","volume":"78","author":"NS Zuckerman","year":"2024","unstructured":"Zuckerman, N. S., Bucris, E., Keidar-Friedman, D., Amsalem, M. & Brosh-Nissimov, T. Nirmatrelvir Resistance-de Novo E166V\/L50V mutations in an immunocompromised patient treated with prolonged Nirmatrelvir\/Ritonavir monotherapy leading to clinical and virological treatment failure-a case report. Clin. Infect. Dis. 78, 352\u2013355 (2024).","journal-title":"Clin. Infect. Dis."},{"key":"69527_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2022.114596","volume":"240","author":"YR Alugubelli","year":"2022","unstructured":"Alugubelli, Y. R. et al. A systematic exploration of boceprevir-based main protease inhibitors as SARS-CoV-2 antivirals. Eur. J. Med Chem. 240, 114596 (2022).","journal-title":"Eur. J. Med Chem."},{"key":"69527_CR40","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1021\/acscentsci.1c00910","volume":"8","author":"W Cao","year":"2022","unstructured":"Cao, W. et al. Evaluation of SARS-CoV-2 main protease inhibitors using a novel cell-based assay. ACS Cent. Sci. 8, 192\u2013204 (2022).","journal-title":"ACS Cent. Sci."},{"key":"69527_CR41","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1124\/mol.113.088526","volume":"85","author":"Y Donmez Cakil","year":"2014","unstructured":"Donmez Cakil, Y. et al. Pore-exposed tyrosine residues of P-glycoprotein are important hydrogen-bonding partners for drugs. Mol. Pharm. 85, 420\u2013428 (2014).","journal-title":"Mol. Pharm."},{"key":"69527_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2022.114570","volume":"240","author":"Y Ma","year":"2022","unstructured":"Ma, Y. et al. A multi-pronged evaluation of aldehyde-based tripeptidyl main protease inhibitors as SARS-CoV-2 antivirals. Eur. J. Med. Chem. 240, 114570 (2022).","journal-title":"Eur. J. Med. Chem."},{"key":"69527_CR43","doi-asserted-by":"publisher","first-page":"11040","DOI":"10.1021\/acs.jmedchem.3c00221","volume":"66","author":"ZZ Geng","year":"2023","unstructured":"Geng, Z. Z. et al. A systematic survey of reversibly covalent dipeptidyl inhibitors of the SARS-CoV-2 main Protease. J. Med Chem. 66, 11040\u201311055 (2023).","journal-title":"J. Med Chem."},{"key":"69527_CR44","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1021\/acsmedchemlett.4c00146","volume":"15","author":"LR Blankenship","year":"2024","unstructured":"Blankenship, L. R. et al. SARS-CoV-2 Main Protease inhibitors that leverage unique interactions with the solvent exposed S3 site of the enzyme. ACS Med. Chem. Lett. 15, 950\u2013957 (2024).","journal-title":"ACS Med. Chem. Lett."},{"key":"69527_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2024.105874","volume":"225","author":"K Khatua","year":"2024","unstructured":"Khatua, K. et al. Azapeptides with unique covalent warheads as SARS-CoV-2 main protease inhibitors. Antivir. Res. 225, 105874 (2024).","journal-title":"Antivir. Res."},{"key":"69527_CR46","doi-asserted-by":"publisher","first-page":"6105","DOI":"10.21873\/anticanres.15430","volume":"41","author":"K Nagai","year":"2021","unstructured":"Nagai, K., Fukuno, S., Shiota, M., Tamura, M., Yabumoto, S. & Konishi, H. Differences in transport characteristics and cytotoxicity of Epirubicin and Doxorubicin in HepG2 and A549 Cells. Anticancer Res. 41, 6105\u20136112 (2021).","journal-title":"Anticancer Res."},{"key":"69527_CR47","doi-asserted-by":"publisher","first-page":"e3001284","DOI":"10.1371\/journal.pbio.3001284","volume":"19","author":"A Muruato","year":"2021","unstructured":"Muruato, A. et al. Mouse-adapted SARS-CoV-2 protects animals from lethal SARS-CoV challenge. PLoS Biol. 19, e3001284 (2021).","journal-title":"PLoS Biol."},{"key":"69527_CR48","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/s41586-023-06609-0","volume":"622","author":"Y Duan","year":"2023","unstructured":"Duan, Y. et al. Molecular mechanisms of SARS-CoV-2 resistance to nirmatrelvir. Nature 622, 376\u2013382 (2023).","journal-title":"Nature"},{"key":"69527_CR49","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/s41586-022-05514-2","volume":"613","author":"S Iketani","year":"2023","unstructured":"Iketani, S. et al. Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir. Nature 613, 558\u2013564 (2023).","journal-title":"Nature"},{"key":"69527_CR50","doi-asserted-by":"crossref","unstructured":"Lockbaum, G. J. et al. Crystal Structure of SARS-CoV-2 Main Protease in Complex with the Non-Covalent Inhibitor ML188. Viruses 13, 174 (2021).","DOI":"10.3390\/v13020174"},{"key":"69527_CR51","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.apsb.2023.08.004","volume":"14","author":"L Song","year":"2024","unstructured":"Song, L. et al. Medicinal chemistry strategies towards the development of non-covalent SARS-CoV-2 Mpro inhibitors. Acta Pharm. Sin. B 14, 87\u2013109 (2024).","journal-title":"Acta Pharm. Sin. B"},{"key":"69527_CR52","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1021\/jm301580n","volume":"56","author":"J Jacobs","year":"2013","unstructured":"Jacobs, J. et al. Discovery, Synthesis, And Structure-Based Optimization of a Series of N-(tert-Butyl)-2-(N-arylamido)-2-(pyridin-3-yl) Acetamides (ML188) as Potent Noncovalent Small Molecule Inhibitors of the Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) 3CL Protease. J. Med. Chem. 56, 534\u2013546 (2013).","journal-title":"J. Med. Chem."},{"key":"69527_CR53","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.chom.2020.04.004","volume":"27","author":"X Xie","year":"2020","unstructured":"Xie, X. et al. An Infectious cDNA Clone of SARS-CoV-2. Cell Host Microbe 27, 841\u2013848 e843 (2020).","journal-title":"Cell Host Microbe"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69527-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69527-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69527-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T17:03:25Z","timestamp":1774458205000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69527-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,14]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["69527"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-69527-5","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,14]]},"assertion":[{"value":"8 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2782"}}